Metropolis Healthcare Ltd (METROPOLIS)
₹545.65
Mkt cap
₹11,320 Cr
P/E ratio
54.40
P/B
7.47
Div yield
0.37%
ROE
13.60%
ROCE
17.80%
EPS (TTM)
₹10.03
Book value
₹73
52W range
412–609
Sector
Healthcare
Price history
Previous close
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
NSE METROPOLISBSE 542650
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−10.41% from high₹546
₹412+32.36% from low₹609
Current
₹545.65
Prev close
₹553.85
Day
−1.48%
Price performance
1D
−1.25%
1W
+4.58%
1M
−2.74%
3M
−6.54%
6M
+14.22%
1Y
+14.18%
YTD
+12.89%
Financials
Revenue, profit & margin
P/E ratio
54.4×
METROPOLIS is 46% above the sector median of 37.4×
METROPOLIS54.4×
Sector median37.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 | |
| Expenses | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 | |
| Operating Profit | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 | |
| OPM % | 23% | 24% | 22% | 24% | 25% | 26% | 22% | 18% | 23% | 25% | 23% | 25% | 25% | |
| Other Income | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | -0 | 8 | 5 | |
| Interest | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 | |
| Depreciation | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 | |
| Profit before tax | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 | |
| Tax % | 26% | 26% | 26% | 28% | 25% | 24% | 26% | 19% | 26% | 26% | 26% | 27% | 27% | |
| Net Profit | 29 | 36 | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 | |
| EPS in Rs | 1.41 | 1.73 | 1.33 | 1.78 | 1.85 | 2.27 | 1.53 | 1.41 | 2.17 | 2.54 | 2.00 | 2.46 | 2.73 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.33% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 4 Aug '26◦ |
| Earnings day | −1.33% |
| +1 day | −3.40% |
| +5 days | −5.49% |
| +15 days | −2.43% |
| +30 days | +0.31% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202647.82%Promoter
Promoters47.82%1.04
FIIs11.67%0.64
DIIs35.49%0.37
Public5.02%0.02
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,906.40 | 56.91 | 31,999 | 0.73% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,445.70 | 79.42 | 14,890 | 0.14% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| Metropolis Healt | ₹545.65 | 54.39 | 11,320 | 0.37% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| Thyrocare Tech. | ₹456.30 | 41.46 | 7,263 | 2.05% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹614.55 | 72.61 | 6,180 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| Suraksha Diagno. | ₹316.35 | 46.02 | 1,648 | 0.16% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Krsnaa Diagnost. | ₹503.75 | 16.52 | 1,634 | 0.40% | 16 | −19.12% | 211 | +19.95% | 12.71% |
| Median: 16 Co. | ₹377.58 | 37.37 | 1,016 | 0.07% | 13 | +25.77% | 103 | +19.10% | 21.90% |
Filings
Annual reports8
Concall transcripts79
TranscriptSep 2026PPTSep 2026RECSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTOct 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptDec 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Metropolis Healthcare will hold Q2FY27 earnings call on November 4, 2026.Board Meeting Intimation for Board Meeting Intimation For Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 And Declaration Of Interim Dividend, If Any, For The Financial Year 2026-27 28 Oct - Board meets November 3, 2026 to approve Q2/H1 results and consider interim dividend.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 14 Oct - Allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026Business Update For Q2FY27 5 Oct - Q2FY27 business update: revenue up ~15% YoY, margins improved; detailed results pending board approval.